Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
An innovative therapeutic strategy to increase the complete resection rate is of utmost
importance in order to enhance survival in colorectal cancer patients with unresectable
liver-only metastasis. Therefore, the investigators propose a prospective study of
neoadjuvant chemotherapy using FOLFOX6 plus cetuximab to convert initially unresectable liver
metastasis to potentially resectable disease.